dministration of the plasminogen activator inhibitor-derived peptide PAI-1dp ameliorated the clinical course of experimental autoimmune encephalomyelitis (EAE). EAE was induced in wild-tupe (WT) mice by immunization with myelin oligodendrocyte glycoprotein (MOG)35–55. The animals were given either placebo or PAI-dp 0.5 mg/kg twice daily by intraperitoneal injection. Results are expressed as the mean clinical score ± standard error (SE) of three separate experiments. (n = 16 for each group). The results are the mean of three separate experiments.